Abstract:Objective?To investigate the depressive disorders in patients with respiratory diseases and analyze the countermeasures against it to provide reference for improving clinical treatment compliance.?Methods?80 cases was selected according to the screening and exclusion criteria from 262 patients with respiratory diseases from January, 2014 to December, 2015. Then divided them randomly into treatment group and control group. The SDS and SAS show no statistical significance before treatment (P > 0.05). The control group with clinical disease symptomatic and supportive treatment, the treatment group combined with anti-anxiety treatment on the basis of clinical symptomatic and supportive group. Then compare the SDS, SAS and dyspnea improvement between the two groups before and after treatment.?Results?The SDS and SAS scores showed no significant difference before treatment (P > 0.05). While after treatment, the SDS and SAS scores in treatment group were significantly lower, and lower than the control group, the difference was statistically significant (P < 0.05). The condition of dyspnea of the two groups show no difference before treatment (P > 0.05). After treatment, the condition of dyspnea improved greater in treatment group than the control group, the difference was statistically significant (P < 0.05).?Conclusions?Because the respiratory disease of patients suffered leads to psychological burden, negative emotional depression anxiety appears not well with the clinical work, by using Deanxit improve patient confidence and compliance, there is a certain positive to improve the clinical symptoms with good clinical value.
